IKS-04 in Pancreatic Ductal Adenocarcinoma: NCT07738939 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
120
Planned enrollment
2028-12-01
Primary-completion proxy
Executive view
NCT07738939 evaluates IKS-04 in Pancreatic Ductal Adenocarcinoma. The disclosed sponsor is Iksuda Therapeutics Ltd., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Recommended Phase 2 Dose (Part I), assessed over Up to 24 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07738939 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Pancreatic Ductal Adenocarcinoma landscape. Drug & Asset MCP drug_fetch was queried for IKS-04, while Company & Deal Intelligence MCP organization_fetch was queried for Iksuda Therapeutics Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07738939 | IKS-04 | Phase 1 / Not yet recruiting | Iksuda Therapeutics Ltd. | United States | Recommended Phase 2 Dose (Part I) Up to 24 months | 2028-12-01 |
| ACTRN12626001037392 | VGT-309 | Not Applicable / Not yet recruiting | Sponsor not reported | Australia | Timing not reported | |
| NCT07777211 | Albumin-Bound Paclitaxel | Phase 1/2 / Active, not recruiting | Beijing Gene Key Life Technology Co., Ltd | China | Incidence of Dose-Limiting Toxicities From the first dose until 42 days | 2027-03-31 |
| NCT07765836 | Vilastobart | Phase 2 / Not yet recruiting | The Massachusetts General Hospital | United States | Objective response rate (ORR) Up to 1 year from baseline. | 2028-12-31 |
| NCT07763301 | YMN-136 Vaccine | Phase 1 / Recruiting | West China Hospital | China | Incidence of Treatment-Related Adverse Events Approximately 24 months | 2028-02-29 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07738939 is a Phase 1, not yet recruiting study with 120 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Recommended Phase 2 Dose (Part I)” over “Up to 24 months.” The retrieved endpoint description is: Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 120 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Pancreatic Ductal Adenocarcinoma. These records do not establish direct evidence for NCT07738939 unless the registration number matches.
A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/…
Phase 2; n=32; Proportion of Participants With an Overall Response = 0.35 proportion of participants (90% Confidence Interval, 0.20 - 0.52); Proportion of Participants With an Overall Response = 0 proportion of participants (90% Confidence Interval, 0 - 0.63) Source: https://clinicaltrials.gov/ct2/show/results/NCT03457948
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Phase 2; n=32; ORR = 0.06 Proportion of participants (95% Confidence Interval, 0.00 - 0.27) Source: https://clinicaltrials.gov/ct2/show/results/NCT04820179
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pan…
Phase 2; n=12; Percentage of Participants With Objective Response Rate = 8.3 Percent of participants (95% Confidence Interval, 0.2 - 38.5) Source: https://clinicaltrials.gov/ct2/show/results/NCT05997056
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
IKS-04 is indexed as Antibody drug conjugate (ADC) with CA 242 x DNA biology and a global stage of Phase 1. The asset profile lists Iksuda Therapeutics Ltd. as an originator or developer.
Iksuda Therapeutics Ltd. is indexed in United Kingdom with the website http://www.iksuda.com. Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics The record lists 8 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether IKS-04 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07738939
Protocol source: https://clinicaltrials.gov/study/NCT07738939
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
IKS-04 in Pancreatic Ductal Adenocarcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Recommended Phase 2 Dose (Part I) and 2028-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
